Literature DB >> 8397890

Adverse effects of newer cephalosporins. An update.

J W Thompson1, R F Jacobs.   

Abstract

While classifications into generations according to antimicrobial activity has helped clinicians incorporate the increasing number of cephalosporins into their pharmacological repertoire, adverse effects among the different agents fail to follow similar categories. In general, cephalosporins are fairly well tolerated antibiotics, and toxicity has been limited to specific agents. Subtle differences in chemical structure and pharmacokinetics can influence the potential for adverse effects. The route of administration may result in minor adverse reactions, including thrombophlebitis and pain. The most common adverse effects of cephalosporins are allergic reactions, occurring in 0.9 to 3.2% of patients. Cephalosporins have very rarely been associated with haematological toxicity (less than 1% of patients), but specific agents have been associated with neutropenia, hypoprothrombinaemia, haemolytic anaemia, and problems with platelet production and function. Other reactions include localised gastrointestinal disturbances, hepatotoxicity (e.g. biliary sludging), nephrotoxicity and mild central nervous system effects. The cephalosporins are generally well tolerated in the paediatric population. Very few interactions have been observed between cephalosporins and other drugs, largely because cephalosporins do not affect the microsomal P450 hepatic enzyme system. While cephalosporins are considered to be relatively 'safe' drugs, the introduction of newer members warrants continued careful observation for reporting of adverse drug reactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397890     DOI: 10.2165/00002018-199309020-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  47 in total

1.  Phase I study of multiple-dose cefprozil and comparison with cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Reversible ceftriaxone-associated biliary pseudolithiasis in children.

Authors:  U B Schaad; J Wedgwood-Krucko; H Tschaeppeler
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

3.  Comparison of ceftriaxone with standard therapy for bacterial meningitis.

Authors:  R W Steele; R W Bradsher
Journal:  J Pediatr       Date:  1983-07       Impact factor: 4.406

4.  Comparative toxicities of third-generation cephalosporins.

Authors:  B R Meyers
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

5.  A double-blind, multicenter, comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients.

Authors:  A Iravani; G A Richard; D Johnson; A Bryant
Journal:  Am J Med       Date:  1988-09-16       Impact factor: 4.965

Review 6.  Third generation cephalosporins: safety profiles after 10 years of clinical use.

Authors:  H C Neu
Journal:  J Clin Pharmacol       Date:  1990-05       Impact factor: 3.126

7.  Production of hypoprothrombinemia by moxalactam and 1-methyl-5-thiotetrazole in rats.

Authors:  J J Lipsky; J C Lewis; W J Novick
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

8.  Hypoprothrombinemia associated with cefoperazone therapy.

Authors:  R J Mueller; D Green; J P Phair
Journal:  South Med J       Date:  1987-11       Impact factor: 0.954

Review 9.  Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.

Authors:  R N Jones
Journal:  Infection       Date:  1985       Impact factor: 3.553

10.  Ceftriaxone therapy of serious bacterial infections.

Authors:  L J Eron; C H Park; R I Goldenberg; D M Poretz
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

View more
  9 in total

Review 1.  AKI associated with cardiac surgery.

Authors:  Robert H Thiele; James M Isbell; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

Review 2.  Drug-induced diarrhoea.

Authors:  O Chassany; A Michaux; J F Bergmann
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 3. 

Authors:  Samiha Mohsen; James A Dickinson; Ranjani Somayaji
Journal:  Can Fam Physician       Date:  2020-09       Impact factor: 3.275

Review 4.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 5.  Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.

Authors:  E Strehl; F Kees
Journal:  Drugs       Date:  2000       Impact factor: 9.546

6.  Cefixime-induced angle closure and transient myopic shift in a healthy individual; A case report.

Authors:  Reza Mirshahi; Mahsa Sardarinia; Naveed Nilforushan
Journal:  Am J Ophthalmol Case Rep       Date:  2020-08-28

Review 7.  Update on the adverse effects of antimicrobial therapies in community practice.

Authors:  Samiha Mohsen; James A Dickinson; Ranjani Somayaji
Journal:  Can Fam Physician       Date:  2020-09       Impact factor: 3.275

Review 8.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

9.  Signal Detection of Adverse Drug Reactions of Cephalosporins Using Data from a National Pharmacovigilance Database.

Authors:  Jung-Yoon Choi; Jae-Hee Choi; Myeong-Gyu Kim; Sandy-Jeong Rhie
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.